Skip to search formSkip to main contentSkip to account menu

response to interleukin-2

Known as: response to IL-2 
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients
Peritoneal ascites are a distinguishable feature of patients with advanced epithelial ovarian cancer (EOC). The presence of… 
2009
2009
Impaired STAT Phosphorylation inTCells fromMelanoma Patients in Response to IL-2 : Associationwith Clinical
Purpose:To assess the extent of signal transducer and activator of transcription (STAT) activation in response to interleukin 2… 
2008
2008
Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia.
The Children’s Cancer Group conducted a randomized comparison of interleukin-2 (IL-2) to no further therapy (control) in… 
2007
2007
Human B Cell Lines and Primary B Cells Actively Secrete Granzyme B in Response to IL-2 Family Cytokines.
It is widely believed that the main function of B cells is antibody secretion, but not cellular cytotoxicity. Recently we found… 
2004
2004
Investigation of FcγR Polymorphisms and Response to IL-2 (Proleukin®) and Rituximab Treatment in Rituximab-Resistant NHL Patients: Importance of the F/F Polymorphism at Position 158 of the Fcγ.
Background: Antibody-dependent cellular cytotoxicty (ADCC) is an important mechanism of rituximab activity. Genetic polymorphisms… 
2002
2002
Response to IL-2 and Bim Kip 1 Regulates Transcription of p 27 The Forkhead Transcription Factor FoxO
1998
1998
Alfentanil Slightly Reduces the Febrile Response to Interleukin-2 Administration
1996
1996
Immunological Response to IL-2 and α-IFN-Treatment After Autologous BMT in Patients with BCR-ABL-positive ALL
Patients with Ph1+/BCR-ABL+ALL have an extremely poor prognosis after treatment with conventional chemotherapy [19, 31]. Bone… 
1992
1992
Platelet Activating Factor Inhibits Both the Proliferation and the Differentiation of Activated B Lymphocytes in Response to Interleukin-2
The role of the platelet activating factor in human B lymphocyte responses to Interleukin-2 was examined and compared with that… 
1985
1985
Interleukin-2 in vivo: production of and response to interleukin-2 in lymphoid organs undergoing a primary immune response to heterologous erythrocytes.
In this report, we describe experiments which demonstrate that antigenic stimulation in vivo causes the appearance of cells in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)